Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reliable predictive marker of early, late PE and whether intrauterine growth restriction (IUGR) as seen in PE is associated with levels of cell-free DNA. Diagnostic criteria for fetal growth retardation are calculated from the results of blood test results obtained in 26-36 weeks of gestation. We performed a PCR assay to compare the cftDNA and cffDNA concentration in maternal plasma among 3 groups of pregnant women. These included 119 women with overt PE (47 - early PE, 72 - late PE), 24 women at risk for the disease who developed PE (8 -early PE, 16 - late PE), and 30 controls. CffDNA quantification is a promising marker for early preeclampsia prediction. Cut-off value of 0,87 ng/ml for cffDNA (87.5 % sensitivity and 66,67 % specificity). Since the increase in cftDNA and cffDNA seems to be related to the presence IUGR in pregnancies which are complicated with early PE. Thus, it suggests that cftDNA and cffDNA could represent a potential biomarker of IUGR among individuals with early PE.
展开▼
机译：子痫前期（PE）是威胁生命的并发症，与孕产妇和围产期的发病率和/或死亡率高相关。这项研究旨在评估母体血浆中的总DNA和胎儿无细胞DNA（cftDNA和cffDNA），以评估这是否可以代表早期，晚期PE的可靠预测标记，以及如在PE中观察到的宫内生长受限（IUGR）是否与无细胞DNA水平有关。胎儿生长发育迟缓的诊断标准是根据妊娠26-36周的血液测试结果得出的。我们进行了PCR分析，比较了三组孕妇中母体血浆中的cftDNA和cffDNA浓度。其中包括119名明显PE的妇女（47名PE早期，72名PE晚期），24名罹患该病的妇女发生PE（8名PE早期，16名PE晚期）和30名对照组。 CffDNA定量是子痫前期预测的有希望的标志。 cffDNA的临界值为0,87 ng / ml（灵敏度为87.5％，特异性为66.67％）。由于cftDNA和cffDNA的增加似乎与妊娠合并早期PE的妊娠中IUGR的存在有关。因此，这表明cftDNA和cffDNA可能代表了早期PE患者中IUGR的潜在生物标记。
展开▼
